Oncology specialists should inform patients about a risk of serious toxicity related to dihydropyrimidine dehydrogenase (DPD) ...
The labeling updates address the risk of early-onset toxicity, including life-threatening adverse events in patients with DPD ...
FDA labeling now recommends DPYD variant testing before initiating capecitabine or 5-FU, except when immediate treatment is ...
The European Medicines Agency (EMA) has started a review into the screening of patients before they begin treatment with certain drugs. Most of the drugs in question are chemotherapies, and they ...
The clinical description of severe toxicity fails to capture the suffering, shock, and tragedy experienced by our loved ones who were fatally overdosed after not being offered this important and ...
Dr. Gabriel A. Brooks discusses what DPD deficiency is and why it is important for patients with cancer receiving 5-FU or Xeloda to be aware of it. The Food and Drug Administration (FDA) has updated ...
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results